U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07415473) titled 'Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease' on Feb. 10.
Brief Summary: This study aims to evaluate whether the combination of Akkermansia muciniphila with infliximab can improve intestinal mucosal healing in patients with Crohn's disease compared with infliximab alone.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Crohn's Diseases
Intervention:
DRUG: Infliximab
Patients will receive infliximab alone administered intravenously at the standard dose of 5 mg/kg at Weeks 0, 2, and 6, followed by every 8 weeks thereafter.
DRUG: Akkermansia mucinip...